The company’s market intelligence arm, FreshLeaf Analytics, predicts a tripling of patient numbers and product volume in the near term.
Director Interviews
Small caps
Zelira Therapeutics accelerates transition to revenue-generation with Zenivol™ and HOPE™ launch in Australia by quarter-end
Zelira is undertaking product development programs targeting specific conditions and human...
The healthcare technology and services company joined the global fight against COVID-19 by...
Life-sciences company eSense-Lab is leading the market in evidence-based terpene product...
The company creates premium phytocannabinoid-based products from its GMP facility in Europe that...
The company has secured agreements to export into Europe, New Zealand and Canada with effect...
Emerald Clinics Ltd (ASX:EMD) CEO Dr Michael Winlo talks to Proactive about his company’s new partnership with Spectrum Biomedical UK to develop a real-world evidence data system in the UK. Shares in the company soared in response to the agreement which will see Emerald design and deliver...
Medical technology & services
Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval...
Medical technology & services
CardieX completes capital raise while also providing insight on...
Pharma & Biotech
Aroa Biosurgery makes its debut on the ASX exchange under code ARX
Basic Materials
Get our market previews and stories before the main networks.
Not just the FTSE. Read about
opportunities from the whole
equities market.
Hear directors at first-hand
or meet them in person at our events.
Watch IPOs and access on the same terms as the institutions.
